Noven Debuts Optional Companion App for Patients with ADHD – Mindful Patch – at APSARD 2025
Noven Pharmaceuticals, Inc., (Noven), a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., and a leader in pharmaceutical innovation, is proud to announce the launch of its groundbreaking app, Mindful Patch, at APSARD 2025 Annual Conference, taking place from January 16th – 19th in San Diego, California.
Noven to Present Pivotal Study Results for Investigational Dextroamphetamine Transdermal System for Pediatric ADHD Patients
Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced it will present the results of a multicenter, phase 2, laboratory classroom study which evaluated the safety and efficacy of its investigational dextroamphetamine transdermal system (“ATS”) in over 100 pediatric patients (ages 6-17 years) with ADHD at the 2021 virtual American Psychiatric Association (APA) Annual Meeting May 1-3, 2021.
